Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Jun 12, 2024 12:21am
148 Views
Post# 36084074

RE:RE:Fitch Ratings

RE:RE:Fitch Ratings"But they have $2B in debt maturities in the next 12 months."

This is the essence of Baxter's debt woes.  Every year they will have about the same amount, if not much more, of debt that needs to be rolled over into new debt.  New debt, with a much higher interest rate than the bonds that originally came due. 

The bonds that Baxter issued for that ill advised Hilrom purchase, were probably issued at around 4% or less, as those bonds mature and come due, the new interest rate is atleast double that rate, actually probably more thanks to their Fitch issues.  The interest expense for their foolish spending is going to be continuously rolling into a much much higher interest rate. 

The 10.5 Billion that Baxter paid for Hilrom was paid for by bonds that Baxter issued in the end of 2021.  Interest rates back then were very friendly to business, today, not so much.  Baxter also assumed 2B of Hilroms debt, and those bonds are surely coming home to roost soon. 

I'm not trying to hate on Baxter, but if I was a shareholder of them, I'd start to be scared that they are going to have to halt their dividend.  Heck maybe that Hilrom hospital bed asset miraculously starts to perform like they thought it would, but going into a contracting economy, I wouldn't bet on it. 

All I'm trying to say is that the PMX distribution rights, is in much better, more financially secure hands, when Baxter finally sells Vantive to PE, and if that PE decides they want the whole kit and caboodle for synergystic reasons, then all the better for us.          
<< Previous
Bullboard Posts
Next >>